Cargando…
Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155444/ https://www.ncbi.nlm.nih.gov/pubmed/37131253 http://dx.doi.org/10.1186/s12967-023-04077-8 |
_version_ | 1785036329865707520 |
---|---|
author | Chen, Xin Bai, Kaixuan Zhang, Yu Xu, Yang Huo, Yinghao Wang, Sha Zou, Yueli Qi, Xuejiao Guo, Rongyun Ou, Qiuxiang Liu, Dengxiang Yin, Shaohua Chen, Shubo Bu, Hui |
author_facet | Chen, Xin Bai, Kaixuan Zhang, Yu Xu, Yang Huo, Yinghao Wang, Sha Zou, Yueli Qi, Xuejiao Guo, Rongyun Ou, Qiuxiang Liu, Dengxiang Yin, Shaohua Chen, Shubo Bu, Hui |
author_sort | Chen, Xin |
collection | PubMed |
description | BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively studied 15 GCLM patients, and all patients had paired primary tumor tissue samples and post-LM CSF samples while 5 patients also had post-LM plasma samples. All samples were analyzed using next-generation sequencing (NGS), and the molecular and clinical features were correlated with clinical outcomes. RESULTS: CSF had higher mutation allele frequency (P = 0.015), more somatic mutations (P = 0.032), and more copy-number variations (P < 0.001) than tumor or plasma samples. Multiple genetic alterations and aberrant signal pathways were enriched in post-LM CSF, including CCNE1 amplification and cell cycle-related genes, and CCNE1 amplification was significantly associated with patients’ overall survival (P = 0.0062). More potential LM progression-related markers were detected in CSF samples than in tumor samples, including PREX2 mutation (P = 0.014), IGF1R mutation (P = 0.034), AR mutation (P = 0.038), SMARCB1 deletion (P < 0.001), SMAD4 deletion (P = 0.0034), and TGF-beta pathway aberration (P = 0.0038). Additionally, improvement in intracranial pressure (P < 0.001), improvement in CSF cytology (P = 0.0038), and relatively low levels of CSF ctDNA (P = 0.0098) were significantly associated with better PFS. Lastly, we reported a GCLM case whose CSF ctDNA dynamic changes were well correlated with his clinical assessment. CONCLUSIONS: CSF ctDNA could more sensitively detect molecular markers and metastasis-related mechanisms than tumor tissues in GCLM patients, and our study sheds light on utilizing CSF ctDNA in prognostic estimation and clinical assessment in GCLM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04077-8. |
format | Online Article Text |
id | pubmed-10155444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101554442023-05-04 Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer Chen, Xin Bai, Kaixuan Zhang, Yu Xu, Yang Huo, Yinghao Wang, Sha Zou, Yueli Qi, Xuejiao Guo, Rongyun Ou, Qiuxiang Liu, Dengxiang Yin, Shaohua Chen, Shubo Bu, Hui J Transl Med Research BACKGROUND: Leptomeningeal metastases (LM) were rare in gastric cancer (GC), and GC patients with LM (GCLM) generally suffer from poor prognosis. Nevertheless, the clinical utility of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was underinvestigated in GCLM. METHODS: We retrospectively studied 15 GCLM patients, and all patients had paired primary tumor tissue samples and post-LM CSF samples while 5 patients also had post-LM plasma samples. All samples were analyzed using next-generation sequencing (NGS), and the molecular and clinical features were correlated with clinical outcomes. RESULTS: CSF had higher mutation allele frequency (P = 0.015), more somatic mutations (P = 0.032), and more copy-number variations (P < 0.001) than tumor or plasma samples. Multiple genetic alterations and aberrant signal pathways were enriched in post-LM CSF, including CCNE1 amplification and cell cycle-related genes, and CCNE1 amplification was significantly associated with patients’ overall survival (P = 0.0062). More potential LM progression-related markers were detected in CSF samples than in tumor samples, including PREX2 mutation (P = 0.014), IGF1R mutation (P = 0.034), AR mutation (P = 0.038), SMARCB1 deletion (P < 0.001), SMAD4 deletion (P = 0.0034), and TGF-beta pathway aberration (P = 0.0038). Additionally, improvement in intracranial pressure (P < 0.001), improvement in CSF cytology (P = 0.0038), and relatively low levels of CSF ctDNA (P = 0.0098) were significantly associated with better PFS. Lastly, we reported a GCLM case whose CSF ctDNA dynamic changes were well correlated with his clinical assessment. CONCLUSIONS: CSF ctDNA could more sensitively detect molecular markers and metastasis-related mechanisms than tumor tissues in GCLM patients, and our study sheds light on utilizing CSF ctDNA in prognostic estimation and clinical assessment in GCLM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04077-8. BioMed Central 2023-05-02 /pmc/articles/PMC10155444/ /pubmed/37131253 http://dx.doi.org/10.1186/s12967-023-04077-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Xin Bai, Kaixuan Zhang, Yu Xu, Yang Huo, Yinghao Wang, Sha Zou, Yueli Qi, Xuejiao Guo, Rongyun Ou, Qiuxiang Liu, Dengxiang Yin, Shaohua Chen, Shubo Bu, Hui Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title | Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title_full | Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title_fullStr | Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title_full_unstemmed | Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title_short | Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer |
title_sort | genomic alterations of cerebrospinal fluid cell-free dna in leptomeningeal metastases of gastric cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155444/ https://www.ncbi.nlm.nih.gov/pubmed/37131253 http://dx.doi.org/10.1186/s12967-023-04077-8 |
work_keys_str_mv | AT chenxin genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT baikaixuan genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT zhangyu genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT xuyang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT huoyinghao genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT wangsha genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT zouyueli genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT qixuejiao genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT guorongyun genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT ouqiuxiang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT liudengxiang genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT yinshaohua genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT chenshubo genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer AT buhui genomicalterationsofcerebrospinalfluidcellfreednainleptomeningealmetastasesofgastriccancer |